Get notified when PCSC files again. Create a free account and we'll email you the moment its next filing is analyzed.
Get filing alertsRed Flags Detected
- Going Concern (new) — Freenome's auditor report includes a going concern explanatory paragraph, indicating substantial doubt about its ability to continue operations.
- Major Deficiency Letter (new) — The FDA has placed the company's PMA for its lead test on hold due to a major deficiency letter, indicating significant regulatory uncertainty.
- Material Weakness (new) — The company acknowledges that testing may reveal material weaknesses in internal controls, which could undermine financial reporting reliability.
Freenome to go public via SPAC merger with Perceptive Capital Solutions, raising $86.2M net proceeds
Filed June 17, 2026 · ~1 min read
Key Changes
-
high
The offering registers up to 82,313,492 shares of common stock, with net proceeds of $86.2 million after underwriting discounts and expenses.
The Offering verify on EDGAR → -
high
Freenome is a pre-revenue cancer screening company with no FDA-approved products; its lead test, SimpleScreen CRC, is under FDA review after a major deficiency letter.
Risk Factors verify on EDGAR → -
high
The company reported net losses of $63.6 million for Q1 2026 and $219.3 million for 2025, with an accumulated deficit of $1.4 billion.
Risk Factors verify on EDGAR →
2 more material changes behind this preview — plus the full narrative summary, section-by-section diffs against the prior filing, and verbatim quotes with EDGAR citations.
Want to see a complete report first? Today's free report (LSAK 10-K) is open in full — no account needed.
Partner
Trade PCSC commission-free
Open an account, get a free stock.
Investing involves risk. Free stock terms apply.
Thanks — your feedback helps us improve report quality.
Figures/quotes linked to EDGAR · Narrative written by AI · Sep 2, 2026 · How we verify